qQ-lab Daily-IBS for Irritable Bowel Syndrome

Status Completed

Clinical Trial Summary

- Primary purpose: To assess satisfaction with overall improvement in symptoms, including individual bowel symptoms, after 4 weeks of administration of gQ-lab to patients with irritable bowel syndrome (IBS).

- Secondary purposes: To assess the correlation between intestinal attachment and therapeutic effects of gQ-lab through the visual analog scale (VAS) assessment of each IBS-related symptom and measurement of changes in quality of life and fecal flora in the placebo group and gQ-lab group after 4 weeks of gQ-lab administration.

To assess safety, including adverse reactions, vital signs (including weight), physical examination, and changes in blood test results.

To examine the rate of positive gut quotient (gQ) values in patients diagnosed with IBS as per the ROME III criteria. Further, to examine how the ROME III-based symptom scale score compared with that of the quality of life scale in the gQ questionnaire.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03964103
Study type	Interventional
Source	IlDong Pharmaceutical Co Ltd
Contact
Status	Completed
Phase	N/A
Start date	October 4, 2016
Completion date	January 22, 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02841878` - Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	N/A
Completed	`NCT02875847` - Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients	Phase 2
Completed	`NCT02842281` - Microbiome Fructan Metabolism and Symptoms in Childhood IBS	N/A
Completed	`NCT02092402` - Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome	N/A
Completed	`NCT00401479` - A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers	Phase 1
Completed	`NCT00421707` - Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome	Phase 2
Not yet recruiting	`NCT06139744` - Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS	Phase 4
Recruiting	`NCT04506593` - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed	`NCT01908465` - Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial	Phase 4
Completed	`NCT01787253` - Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
Completed	`NCT00376896` - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers	Phase 1
Completed	`NCT00904696` - Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome	N/A
Recruiting	`NCT05453084` - Exercise and Irritable Bowel Syndrome (IBS)	N/A
Completed	`NCT03550742` - Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients	N/A
Terminated	`NCT01887002` - Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)	Phase 2
Completed	`NCT01774695` - Physical Activity in IBS - a Long Term Follow up	N/A
Completed	`NCT01204515` - Abdominal Symptom Phenotype Study in Children	N/A
Completed	`NCT00067457` - Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy	Phase 3
Completed	`NCT00067561` - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy	Phase 3
Not yet recruiting	`NCT05630703` - Mindfulness Training Versus Low (FODMAP) Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols Diet	N/A